Risks and benefits of psychotropic medication in pregnancy: cohort studies based on UK electronic primary care health records

Irene Petersen,1* Rachel L McCrea,1 Cormac J Sammon,1 David PJ Osborn,2 Stephen J Evans,3 Phillip J Cowen,4 Nick Freemantle1 and Irwin Nazareth1

1Department of Primary Care and Population Health, University College London, London, UK
2Division of Psychiatry, University College London, London, UK
3Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK
4University Department of Psychiatry, Warneford Hospital, Oxford, UK

*Corresponding author

Declared competing interest of authors: Phillip J Cowen has, in the last 3 years, been a paid member of an advisory board of Lundbeck. Nick Freemantle has received funding for research and consultancy from a variety of governmental, industrial, and charitable sources. Cormac J Sammon has received funding for research from Novartis Vaccines and Diagnostics. Irene Petersen supervises a PhD student who is sponsored by Novo Nordisk. Irwin Nazareth is currently a member of the National Institute for Health Research Health Technology Assessment commissioning board.

Published March 2016
DOI: 10.3310/hta20230

Plain English summary

Risks and benefits of psychotropic medication in pregnancy

Health Technology Assessment 2016; Vol. 20: No. 23
DOI: 10.3310/hta20230

NIHR Journals Library www.journalslibrary.nihr.ac.uk
Plain English summary

Many women with bipolar disorder and schizophrenia become pregnant, but there is a lack of information about the advantages and disadvantages of using psychotropic drugs such as antipsychotics, valproate (multiple manufacturers) and lithium (multiple manufacturers) to treat these conditions in pregnancy. This makes it difficult for women and their health-care professionals to decide whether or not these should be used in pregnancy.

We used anonymised information from a large database of general practitioner (GP) records to investigate when women were taking psychotropic drugs. We then used information recorded by the GPs to examine if the drug had any impact on pregnancy outcomes. As there are three main types of psychotropic drug (antipsychotics, anticonvulsants and lithium) we did our study separately for each type.

The number of pregnant women using antipsychotics and anticonvulsants increased over time but the number using lithium did not. Many women stopped drug treatment before pregnancy or in early pregnancy and started again in late pregnancy or after they delivered. Women who were prescribed antipsychotics in pregnancy had worse pregnancy outcomes. However, they were also more likely to be obese, drink, smoke, be prescribed other medication and use illicit drugs than women not prescribed antipsychotics. These factors may, to some extent, be associated with the worse pregnancy outcomes. Women who used anticonvulsants in pregnancy had worse child outcomes than those who did not. In particular, women who were prescribed one anticonvulsant drug, valproate, in pregnancy had an increased risk of giving birth to a child with major malformations.
Criteria for inclusion in the Health Technology Assessment journal

Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme

The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. ‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta

This report

The research reported in this issue of the journal was funded by the HTA programme as project number 11/35/06. The contractual start date was in May 2013. The draft report began editorial review in June 2015 and was accepted for publication in October 2015. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health.

© Queen’s Printer and Controller of HMSO 2016. This work was produced by Petersen et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).
Health Technology Assessment Editor-in-Chief

Professor Hywel Williams  Director, HTA Programme, UK and Foundation Professor and Co-Director of the Centre of Evidence-Based Dermatology, University of Nottingham, UK

NIHR Journals Library Editor-in-Chief

Professor Tom Walley  Director, NIHR Evaluation, Trials and Studies and Director of the HTA Programme, UK

NIHR Journals Library Editors

Professor Ken Stein  Chair of HTA Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

Professor Andree Le May  Chair of NIHR Journals Library Editorial Group (EME, HS&DR, PGfAR, PHR journals)

Dr Martin Ashton-Key  Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

Professor Matthias Beck  Chair in Public Sector Management and Subject Leader (Management Group), Queen’s University Management School, Queen’s University Belfast, UK

Professor Aileen Clarke  Professor of Public Health and Health Services Research, Warwick Medical School, University of Warwick

Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK

Dr Peter Davidson  Director of NETSCC, HTA, UK

Ms Tara Lamont  Scientific Advisor, NETSCC, UK

Professor Elaine McColl  Director, Newcastle Clinical Trials Unit, Institute of Health and Society, Newcastle University, UK

Professor William McGuire  Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads  Professor of Health Sciences Research, Health and Wellbeing Research and Development Group, University of Winchester, UK

Professor John Norrie  Health Services Research Unit, University of Aberdeen, UK

Professor John Powell  Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

Professor James Raftery  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts  Professor of Child Health Research, UCL Institute of Child Health, UK

Professor Jonathan Ross  Professor of Sexual Health and HIV, University Hospital Birmingham, UK

Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Professor Jim Thornton  Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Please visit the website for a list of members of the NIHR Journals Library Board:
www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: nihredit@southampton.ac.uk